Why a treatment name is not a treatment history
When you send records for chemotherapy planning in China, the receiving clinician needs to reconstruct what your cancer did under each treatment. A line such as 'carboplatin and paclitaxel' identifies the drugs but says nothing about whether the tumour shrank, stayed stable, grew, or whether you stopped because of toxicity, progression or another reason. Those are different clinical situations, and they can lead to different discussions about what to try next.
Chemotherapy uses drugs to kill or slow the growth of cancer cells, and treatment schedules differ according to the prescribed regimen. That is why the same drug name can appear in very different histories. Two patients may both have received the same regimen, but one completed all planned cycles with a good response while the other stopped after two cycles because of side effects. The name alone cannot distinguish them.
For an overseas review, your goal is not to write a perfect medical summary. It is to give the treating team enough structured information that they can see the sequence, the response and the unresolved questions. They will interpret it; you do not need to decide what it means.
What to record for each previous regimen
Organise your history regimen by regimen, in date order. For each one, try to answer the same set of questions. If you do not know an answer, write 'not known' rather than leaving it blank or guessing. A clear gap is more useful than a vague statement.
Start with the regimen name or the drugs used, and whether it was given by infusion, injection or orally. Add the start and end dates, and how many cycles were planned compared with how many you actually completed. Then describe the response: what did the scans show, and what words did your treating team use? Terms such as complete response, partial response, stable disease or progression are meaningful, but only if they came from your own clinicians. If you were told 'it was working' or 'it stopped working', quote that wording and note who said it.
Record the reason the regimen stopped. This may be completion of planned treatment, disease progression, unacceptable side effects, a decision to switch, or another reason. Also note the main side effects and how they were managed, because this affects what a new team may consider tolerable.
Finally, note what treatment came next and when. A gap between regimens, or a switch to a different drug class, is part of the history. If you received radiotherapy, surgery, targeted therapy or immunotherapy in the same period, include it with dates so the sequence is clear.
- Regimen name or drugs, and how they were given.
- Start and end dates, cycles planned and cycles completed.
- Response as described by your own treating team, with the scan or assessment date.
- Reason for stopping, including progression, toxicity or completion.
- Main side effects and how they were managed.
- What treatment followed, and when.
The documents that make the description credible
Your written summary is a guide; the source documents are the evidence. A China oncology team will want to see the reports behind your description, not only your account of them. Ask whether the review concerns a new regimen or ongoing treatment, because that changes which records matter most.
For each regimen, try to include the pathology report that confirmed the diagnosis, imaging reports before and after treatment, and blood test results that tracked response or toxicity. Discharge summaries and clinic letters are valuable because they often contain the treating team's own assessment of response and the reason for stopping. If a report is in another language, ask whether a translated summary is needed and who should prepare it.
You do not need to send everything at once. A short initial summary with the key reports is enough to start. After first contact, the team can tell you what else would help. Do not send passport numbers, card details or a complete archive through an initial enquiry form.
Describing response without overstating it
Patients often worry that their description will be judged. The safer approach is to separate what a report says from what you were told. For example, 'CT report dated March 2025 described reduction in the lung lesion' is a fact from a document. 'My doctor said the treatment was working well' is a recollection. Both are useful, but they should not be blended into one claim.
Avoid converting a scan impression into a percentage or a formal response category unless your own clinicians used that language. Do not describe a treatment as having 'failed' if you were actually switched for toxicity. Do not describe a response as complete if the report used a softer phrase. Precision here helps the receiving team understand the real trajectory.
If you are unsure how to describe something, write the question you want answered. For example: 'I do not know whether the April scan showed stable disease or slight progression; please advise what the report indicates.' That is a legitimate and useful entry.
What the China team still has to confirm
A records-based review can clarify the history and discuss possible directions, but it does not establish that a particular regimen is available, suitable or reimbursable for you. The treating hospital decides suitability after assessing your records and, where needed, further tests. Availability of specific drugs, clinical trial options and ward arrangements are questions for the named provider.
Ask the provider how it would coordinate treatment cycles and monitoring if you were to receive care there. This includes how often you would need to be present, how blood tests and imaging would be scheduled, and how communication with your home team would work. These are practical questions that affect travel and planning, and they should be answered by the hospital rather than assumed.
If you are currently receiving treatment, do not delay or interrupt it to arrange an overseas enquiry. Urgent or worsening symptoms need local assessment first. An overseas review is a planning step, not a reason to pause necessary care.
A practical next step
Write a one-page summary using the regimen-by-regimen structure above, attach the key reports, and state your main question clearly. Before you send anything, decide which of two questions you are actually asking: whether a new regimen might be considered, or whether ongoing treatment could be continued or adjusted in China. The records that matter, and the way the team reads them, differ between those two situations. Say which one applies in your first message so the reply is aimed at the right decision.
Then make the enquiry specific. Name the cancer type and stage as recorded in your own reports, list each prior regimen with its dates and outcome, and ask what additional documents the hospital would need before it can comment. Ask directly how treatment cycles and monitoring would be coordinated if you were to receive care there: how often you would need to be present, how blood tests and imaging would be scheduled around each cycle, and how the team would communicate with your current oncologist. Those answers shape travel, cost and timing far more than a general price question does.
If you would like help identifying what is missing from your summary and which route may fit, you can start with a free initial case review. It is not a diagnosis or a promise of acceptance, and it does not require buying a proxy consultation. The hospital decides suitability.
You can also read the chemotherapy planning reference for an overview of how treatment is organised before you send records.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.